$0.70
0.0284[4.23%]
At close: Apr 25
$0.70
0[0.00%]
After Hours: 4:20PM EDT
Cara Therapeutics
(NASDAQ:CARA)Cara Therapeutics Stock (NASDAQ:CARA), Analyst Ratings, Price Targets, Predictions
Cara Therapeutics Inc has a consensus price target of $11.61, established from looking at the 32 latest analyst ratings. The last 3 analyst ratings were released from Needham, Needham, and Canaccord Genuity on April 10, 2024, March 28, 2024, and March 6, 2024. With an average price target of $6.67 between Needham, Needham, and Canaccord Genuity, there's an implied 852.38% upside for Cara Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Canaccord Genuity
HC Wainwright & Co.
Piper Sandler
Stifel
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cara Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | CARA | Buy Now | Cara Therapeutics | $0.70 | 614.29% | Needham | Joseph Stringer | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | CARA | Buy Now | Cara Therapeutics | $0.70 | 614.29% | Needham | Joseph Stringer | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | CARA | Buy Now | Cara Therapeutics | $0.70 | 1328.57% | Canaccord Genuity | Sumant Kulkarni | $11 → $10 | Maintains | Buy | Get Alert |
| 03/05/2024 | CARA | Buy Now | Cara Therapeutics | $0.70 | 614.29% | Needham | Joseph Stringer | → $5 | Reiterates | Buy → Buy | Get Alert |
| 01/22/2024 | CARA | Buy Now | Cara Therapeutics | $0.70 | 614.29% | Needham | Joseph Stringer | $6 → $5 | Maintains | Buy | Get Alert |
| 12/19/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 257.14% | HC Wainwright & Co. | Oren Livnat | $7 → $2.5 | Maintains | Buy | Get Alert |
| 12/18/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 757.14% | Needham | Joseph Stringer | $22 → $6 | Maintains | Buy | Get Alert |
| 11/14/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 42.86% | Piper Sandler | David Amsellem | $12 → $1 | Downgrade | Overweight → Neutral | Get Alert |
| 10/19/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 900% | HC Wainwright & Co. | Oren Livnat | $15 → $7 | Maintains | Buy | Get Alert |
| 08/08/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 1614.29% | Piper Sandler | David Amsellem | $13 → $12 | Maintains | Overweight | Get Alert |
| 08/08/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 3042.86% | Needham | Joseph Stringer | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 3900% | Stifel | Annabel Samimy | → $28 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 2471.43% | Jefferies | Dennis Ding | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 2042.86% | HC Wainwright & Co. | Oren Livnat | $20 → $15 | Maintains | Buy | Get Alert |
| 05/16/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 471.43% | B of A Securities | Jason Gerberry | $6 → $4 | Maintains | Underperform | Get Alert |
| 05/16/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 3042.86% | Needham | Joseph Stringer | → $22 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 3042.86% | Needham | Joseph Stringer | → $22 | Reiterates | → Action List Buy | Get Alert |
| 04/04/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 3042.86% | Needham | Joseph Stringer | → $22 | Reiterates | → Buy | Get Alert |
| 03/08/2023 | CARA | Buy Now | Cara Therapeutics | $0.70 | 757.14% | B of A Securities | Jason Gerberry | $13 → $6 | Downgrade | Neutral → Underperform | Get Alert |
FAQ
What is the target price for Cara Therapeutics (CARA)?
The latest price target for Cara Therapeutics (NASDAQ: CARA) was reported by Needham on April 10, 2024. The analyst firm set a price target for $5.00 expecting CARA to rise to within 12 months (a possible 614.29% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cara Therapeutics (CARA)?
The latest analyst rating for Cara Therapeutics (NASDAQ: CARA) was provided by Needham, and Cara Therapeutics reiterated their buy rating.
When was the last upgrade for Cara Therapeutics (CARA)?
The last upgrade for Cara Therapeutics Inc happened on March 8, 2022 when JP Morgan raised their price target to $20. JP Morgan previously had a neutral for Cara Therapeutics Inc.
When was the last downgrade for Cara Therapeutics (CARA)?
The last downgrade for Cara Therapeutics Inc happened on November 14, 2023 when Piper Sandler changed their price target from $12 to $1 for Cara Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Cara Therapeutics (CARA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cara Therapeutics was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Cara Therapeutics (CARA) correct?
While ratings are subjective and will change, the latest Cara Therapeutics (CARA) rating was a reiterated with a price target of $0.00 to $5.00. The current price Cara Therapeutics (CARA) is trading at is $0.70, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.